CAR T-hujayra terapiyasi Narxi Hindiston

CAR T-hujayra terapiyasi nima?

CAR T-hujayra terapiyasi saraton kasalligiga qarshi kurashish uchun tanangizning o'z immun tizimidan foydalanadigan ilg'or saraton davolash turidir. uchun turadiKimerik antigen retseptorlari T-hujayra terapiyasi. Bu jarayonda shifokorlar bemorning T-hujayralari (infektsiyalardan himoyalanishga yordam beradigan oq qon hujayralari) to'playdi va ularni saraton hujayralarini tanib olish va o'ldirish uchun qayta dasturlashadi.

T-hujayralari laboratoriyada ularning yuzasida maxsus retseptorlarni (CAR) o'tkazish uchun o'zgartiriladi. Ushbu retseptorlar T-hujayralarini saraton hujayralarida joylashgan maxsus oqsillarga bog'lash imkonini beradi. Ushbu "qo'shimcha zaryadlangan" hujayralar bemorning tanasiga qaytarilgach, ular saraton hujayralarini faol ravishda qidiradi va yo'q qiladi.

Ushbu terapiya juda maqsadli, ya'ni sog'lom to'qimalarni saqlagan holda saratonga hujum qiladi. Ba'zi qon saratonlarini davolashda muhim ahamiyatga egaB hujayrali limfoma, o'tkir limfoblastik leykemiya (ALL),vako'p miyelom, ayniqsa, kimyoterapiya yoki radiatsiya kabi boshqa muolajalar muvaffaqiyatsizlikka uchraganda.

CAR T-hujayra terapiyasi onkologiyadagi o'yinni o'zgartiruvchi bo'lib, davolash imkoniyatlari cheklangan saraton bemorlariga umid beradi. Davolash standart saraton davolash usullaridan farq qiladi, bu esa ilgari tiklanish imkoniyati kam bo'lgan ko'plab bemorlarga uzoq muddatli remissiya beradi.

CAR T-hujayrali terapiya kimga kerak?

CAR T-hujayrali terapiyasi qon saratonining o'ziga xos turlari bo'lgan odamlar uchun, ayniqsa kimyoterapiya, radiatsiya yoki ildiz hujayra transplantatsiyasi kabi an'anaviy davolash usullari ishlamaganida qo'llaniladi. Bu birinchi darajali davo emas, balki relapsli yoki refrakter saratoni bo'lgan bemorlar uchun kuchli imkoniyatdir, ya'ni kasallik qaytib kelgan yoki oldingi davolashlarga javob bermagan.

Ushbu terapiya eng ko'p qo'llaniladi:

• B-hujayrali o'tkir limfoblastik leykemiya (ALL): Ayniqsa, standart muolajalarga javob bermagan bolalar va yoshlarda.
• Diffuz katta B hujayrali lenfoma (DLBCL)Xodgkin bo'lmagan limfomaning boshqa turlari: kamida ikki qatorli tizimli terapiya muvaffaqiyatsizlikka uchragan bemorlar uchun.
• Ko'p miyelom: Ayniqsa, proteazoma inhibitörleri yoki monoklonal antikorlarni o'z ichiga olgan boshqa davolash usullari endi samarali bo'lmaganda.

CAR T-hujayra terapiyasiga munosib bo'lish uchun saraton bemorlar muayyan shartlarga javob berishi kerak:

• Saraton CAR T-hujayralari nishonga olishi mumkin bo'lgan o'ziga xos belgilarni (masalan, CD19 yoki BCMA) ifodalashi kerak.
• Bemor davolanish jarayonini, shu jumladan har qanday nojo'ya ta'sirlarni boshqarish uchun etarlicha sog'lom bo'lishi kerak.
• Bemorda nazoratsiz infektsiyalar yoki jiddiy organ etishmovchiligi bo'lmasligi kerak.
• Ko'pgina hollarda, CAR T-hujayra terapiyasini ko'rib chiqishdan oldin, odatda, boshqa davolash usullarining oldingi muvaffaqiyatsizligi talab qilinadi.

Shifokorlar tasdiqlashdan oldin turli xil testlarni o'tkazadilar, jumladan, qon testlari, tasviriy tadqiqotlar va organlar faoliyatini baholash. Muvofiqlik, shuningdek, tasdiqlangan CAR T-hujayra mahsulotlarining mavjudligiga va davolash o'tkazilayotgan mamlakatda saraton kasalligining o'ziga xos turi uchun me'yoriy ruxsatlarga bog'liq.

CAR T-hujayra terapiyasi tartibi

CAR T-hujayra terapiyasi ehtiyotkorlik bilan rejalashtirilgan, bosqichma-bosqich jarayondir. Bu sizning immunitet hujayralaringizni to'plashni, saratonni aniqlashi uchun ularni laboratoriyada o'zgartirishni va keyin ularni kasallik bilan kurashish uchun tanangizga qaytarishni o'z ichiga oladi. Bu boshidan oxirigacha qanday ishlaydi:

1. Leykaferez (T-hujayralar to'plami):Jarayon leykaferez deb ataladigan protsedura bilan boshlanadi. Bemordan qon tomir orqali olinadi va mashina T-hujayralarini (oq qon hujayralarining bir turi) ajratadi. Qonning qolgan qismi tanaga qaytariladi. Jarayon bir necha soat davom etadi va ambulatoriya tartibida amalga oshiriladi.
2. Laboratoriyada hujayra muhandisligi:Yig'ilgan T-hujayralari genetik jihatdan o'zgartirilgan laboratoriyaga yuboriladi. Laboratoriya mutaxassislari T-hujayralariga yangi genni kiritib, ularni Ximer antigen retseptorlari (CAR) deb nomlangan maxsus retseptor bilan jihozlashadi. Ushbu CAR hujayralarga saraton hujayralaridagi o'ziga xos oqsillarni tanib olish va biriktirishga yordam beradi.
3. Hujayralarni ko'paytirish:T-hujayralari ishlab chiqilgandan so'ng, ular laboratoriyada ko'p miqdorda o'stiriladi. Bu 2 dan 3 haftagacha davom etishi mumkin. Maqsad saraton hujayralarini yo'q qila oladigan millionlab kuchli CAR T hujayralarini yaratishdir.
4. Konditsioner terapiyasi (infuziondan oldingi kimyoterapiya):CAR T-hujayralarini yuborishdan oldin, bemorlar odatda 3-5 kun davom etadigan qisqa muddatli kimyoterapiya kursidan o'tadilar. Bu immunitet tizimini biroz zaiflashtirishga yordam beradi, bu esa yangi CAR T-hujayralari tanaga kirgandan so'ng kengayishiga va yanada samarali ishlashiga imkon beradi.
5. CAR T-hujayra infuzioni:Laboratoriyada tayyorlangan hujayralar tayyor bo'lgach, ular bemorga tomir ichiga yuboriladi. Infuzion qon quyishga o'xshaydi va odatda 30 dan 90 minutgacha davom etadi. Odatda kasalxonada yaqin nazorat ostida amalga oshiriladi.
6. Kuzatish va tiklash:Infuziondan so'ng, bemorlar kamida bir hafta davomida har qanday nojo'ya ta'sirlarni aniqlash uchun diqqat bilan kuzatiladi. Ba'zilar bu davrda kasalxonada qolishi mumkin, boshqalari esa ambulatoriya sifatida kuzatiladi. Davolashning muvaffaqiyatini baholash va har qanday asoratlarni boshqarish uchun keyingi tashriflar, qon testlari va skanerlar o'tkaziladi.

Vaqt jadvaliga umumiy nuqtai:T-hujayralarni to'plashdan infuziyagacha, butun CAR T-hujayralarini davolash jarayoni odatda 3 dan 6 haftagacha davom etadi. Qayta tiklash va kuzatish tananing davolanishga javobiga qarab bir necha oy davom etishi mumkin.

Ushbu shaxsiylashtirilgan davolash sizning immunitet tizimingizni saraton kasalligiga qarshi kurashishga o'rgatadi va ko'pchilik uchun boshqa variantlar muvaffaqiyatsizlikka uchraganida yangi umid beradi.

What is the Cost of CAR T-Cell Therapy in India?

The cost of CAR T-cell therapy in India ranges from ₹45,00,000 to ₹70,00,000, which is approximately $52,000 to $85,000. The price is significantly lower than what patients pay in the US or Europe, where similar treatment can exceed $400,000.

This pricing covers much more than just the procedure. In India, most hospitals offer a comprehensive package that includes the entire treatment journey, from your first consultation to your recovery phase. Below is a list of what's typically included in the cost.

• Consultation with Oncology and Transplant Specialists: Covers all pre-treatment discussions and evaluations.
• Leukapheresis Procedure: This process involves collecting T-cells from the patient.
• T-cell Engineering and Manufacturing: This is the most expensive part. It includes modifying the patient's cells in a certified lab using advanced technologies.
• Hospital Admission and ICU Stay (if needed): Includes general ward or ICU expenses during infusion and post-infusion observation.
• Pre-Infusion Chemotherapy: Conditioning therapy to prepare the body for CAR T-cell infusion.
• CAR T-cell Infusion Procedure: Safe administration of the modified cells.
• Post-treatment medications include immunosuppressants, antibiotics, and other drugs to manage side effects.
• Diagnostics and Monitoring: Covers tests like PET scans, CBC, liver/kidney function tests, ECGs, and others throughout the process.
• Follow-up Care for 3–6 Months: Routine check-ups, blood work, and progress tracking after discharge.

The cost may vary slightly depending on your hospital choice, the complexity of your case, and the type of cancer being treated. Still, even the highest range in India remains far more affordable than in the West, making India a preferred destination for this advanced cancer therapy.

Cost Breakdown of CAR T-cell Therapy in India

Knowing the individual components that comprise the total cost of CAR T-cell therapy in India enables patients to plan more effectively. While the complete CAR T-cell treatment package ranges between ₹45,00,000 and ₹70,00,000 ($52,000–$85,000), here's a breakdown of where that money goes:

To begin with, the initial consultation and oncology evaluation costs between ₹10,000 and ₹25,000. It includes a detailed discussion with the cancer specialist, a clinical examination, and the development of a personalized treatment plan.

Next, patients undergo diagnostic tests and imaging, such as PET-CT scans, MRIs, complete blood work, and organ function tests. These are essential to assess disease stage and overall health. This stage usually costs between ₹1,00,000 and ₹2,00,000.

Once cleared for treatment, patients undergo leukapheresis, a process that involves collecting T-cells from the blood. This procedure alone costs around ₹3,00,000 to ₹5,00,000 in most Indian cancer centers.

The most expensive and critical stage is T-cell engineering, where the collected T-cells are modified in a high-tech laboratory to target cancer cells. This step, also known as cell manufacturing, can cost anywhere from ₹25,00,000 to ₹40,00,000 depending on the type of CAR construct used.

Before re-infusing the engineered cells, patients often receive preconditioning chemotherapy. It weakens the existing immune system to make space for the new CAR T-cells. The cost for this preparatory chemotherapy ranges between ₹1,00,000 and ₹2,50,000.

The actual CAR T-cell infusion is done in a hospital setting and may be a short-stay or daycare procedure. The infusion cost is approximately ₹1,50,000 to ₹3,00,000, depending on hospital protocols and the need for special monitoring.

After infusion, patients are typically observed in the hospital for several days to manage side effects and prevent complications. Hospital stay and ICU charges, if needed, add around ₹3,00,000 to ₹6,00,000 to the total cost.

Patients may also require a wide range of medications to manage side effects, such as steroids, antibiotics, painkillers, and immunosuppressants. These supportive medicines cost between ₹2,00,000 and ₹4,00,000 throughout treatment.

Lastly, post-treatment follow-up care (including routine check-ups, lab tests, and response monitoring over the next three to six months) can cost ₹1,00,000 to ₹2,00,000, depending on the frequency of follow-ups and the patient's recovery status.

The transparent cost structure ensures that patients and their families are aware of exactly where their expenses are allocated. In most Indian hospitals, the team also provides pre-approval for international patients to avoid hidden costs.

First Made in India CAR T-Cell Therapy

India made a significant leap in advanced cancer care with the launch of its first homegrown CAR T-cell therapy — NexCAR19. This breakthrough marked an important turning point, making cutting-edge cancer treatment more affordable and accessible to both Indian and international patients.

NexCAR19 was developed through a collaboration between ImmunoACT, a company started at the Indian Institute of Technology (IIT) Bombay, and Tata Memorial Centre, one of India's most trusted cancer institutes. After years of research, clinical trials, and rigorous safety checks, the therapy received regulatory approval in late 2023. It was officially launched in January 2024, offering new hope to patients battling resistant blood cancers.

What makes NexCAR19 special is that it's manufactured within India. In-country manufacturing drastically reduces the cost compared to imported therapies, which used to cost over ₹3–5 crore (more than $400,000). In contrast, NexCAR19 is priced around ₹40,00,000 to ₹50,00,000, making it far more affordable without compromising on quality or safety.

NexCAR19 is currently approved for use in B-cell lymphomas and B-acute lymphoblastic leukemia (B-ALL) that do not respond to standard treatments. It has already shown promising results in early clinical trials, with several patients achieving remission after receiving the therapy.

India's entry into the global CAR T-cell therapy space with NexCAR19 signals a new era of cost-effective, high-tech cancer treatment. Patients from other countries are also starting to consider India as a serious destination for this life-saving option, thanks to the availability of NexCAR19, top-tier oncology centers, and experienced hematologists.

CAR T-cell Therapy Cost Comparison With Different Countries

CAR T-cell therapy is one of the most advanced cancer treatments available, but its cost can vary depending on where it is performed. India is a leading destination for CAR T-cell therapy due to its affordable pricing and world-class medical infrastructure. Here's a comparison of costs across major countries:

As seen above, CAR T-cell therapy in India is nearly 70%–90% more affordable compared to the US, UK, or Germany. Even countries like Singapore and the UAE, which are often considered for medical tourism, have significantly higher prices.

The reduced cost in India does not mean any compromise on quality. Hospitals offering CAR T-cell therapy in India use cutting-edge equipment, advanced immunotherapy labs, and globally trained oncologists. Moreover, with India developing its own CAR T-cell products, such as NexCAR19, the cost is expected to remain within reach for a larger number of patients.

What are the Factors Affecting CAR T-cell Therapy Cost in India?

The cost of CAR T-cell therapy in India can vary from patient to patient. While the average cost ranges between ₹45 lakh and ₹70 lakh, several essential factors can push the price higher or lower. Knowing these cost influencers can help patients and their families plan better.

• Type of Cancer Treated: The cost varies based on the type of cancer, such as B-cell lymphoma, acute lymphoblastic leukemia (ALL), or multiple myeloma. Some cancers need more intensive care and longer treatment cycles.
• Choice of Hospital: Premium hospitals with advanced CAR T-cell labs and ICU facilities may charge more. However, these centers often offer higher success rates and better patient care.
• Type of CAR T-cell Used: India now offers both imported and indigenous options, like NexCAR19. Locally developed therapies are more cost-effective than imported ones.
• Patient's Condition and Stage: Advanced cancer stages may require additional treatment, an ICU stay, or a more extended hospitalization. It can increase the overall cost of CAR T-cell therapy.
• Diagnostic and Pre-Treatment Workup: Before the actual treatment, multiple tests, including PET scans, blood panels, and organ function checks, are necessary. These add to the total cost.
• Hospital Stay and Recovery Time: A longer hospital stay, especially if the patient needs intensive monitoring, will raise the cost. Some may also need post-treatment rehabilitation.
• Post-Treatment Monitoring and Medications: Regular follow-ups, blood tests, and supportive medications are required after infusion. These ongoing costs depend on the patient's response to treatment.
• Support Services for International Patients: Additional services, such as visa assistance, private rooms, translators, and post-discharge support, may incur an extra cost for foreign patients.

Why Choose India for CAR T-cell Therapy?

India is emerging as a trusted global destination for advanced cancer treatments, such as CAR T-cell therapy. With a combination of cutting-edge technology, expert doctors, and affordable prices, India presents a compelling alternative to the expensive treatments available in the US or Europe.

• Affordable CAR T-cell Treatment: India offers CAR T-cell therapy at a much lower cost than the US or Europe, with prices starting from ₹45 lakhs ($52,000), without compromising on quality.
• World-Class Cancer Hospitals: Leading Indian hospitals are equipped with state-of-the-art CAR T-cell labs, ICU facilities, and highly experienced oncology teams.
• Experienced Oncologists and Scientists: Indian doctors and researchers are at the forefront of immunotherapy, offering personalized care and expertise in treating complex cancers.
• Access to Indigenous CAR T-Cell Therapy: India now has its own FDA-approved CAR T-cell treatment, such as NexCAR19, which is both effective and cost-saving for patients.
• Faster Access and Shorter Waiting Times: Unlike in Western countries, patients in India can initiate CAR T-cell therapy promptly, which is particularly crucial for aggressive cancers such as B-cell lymphoma.
• Ideal for International Patients: India's cancer centers offer dedicated services for foreign patients, encompassing everything from airport pickup to post-treatment follow-up care.
• Availability of Clinical Trials: India is actively conducting CAR T-cell therapy trials, providing eligible patients with access to cutting-edge treatments at a reduced cost.

What are the Services Available for International Patients Seeking CAR T-cell Therapy in India?

Traveling abroad for advanced treatment like CAR T-cell therapy can feel overwhelming. To make your journey stress-free, top cancer hospitals in India offer end-to-end support tailored specifically for international patients. The assistance ranges from visa help and airport pickup to translators and post-treatment follow-ups.

• Visa and Travel Assistance: Top hospitals in India offer help with medical visa invitations, quick documentation, and even priority appointments to ease your travel planning.
• Airport Pickup and Local Transport: Hospitals arrange airport pickup, local transport, and even hospital shuttles to ensure a smooth and safe journey from arrival to treatment.
• Affordable Accommodation Options: Partner guesthouses and nearby hotels offer clean and budget-friendly stays for patients and their families, often within walking distance of the hospital.
• Translator and Language Support: Language won't be a barrier. Many hospitals have multilingual staff or arrange interpreters for languages such as Arabic, French, Russian, Spanish, and others.
• Dedicated International Patient Departments: Special teams are assigned to guide international patients through each step, from admission to discharge, ensuring personalized care and comfort.
• Currency Exchange and Payment Support: Hospitals provide on-site foreign exchange services and accept multiple payment methods, including international credit cards, wire transfers, and medical insurance, where applicable.
• Post-Treatment Follow-Up: You'll receive regular updates and online consultations after returning home, ensuring your recovery and monitoring continue uninterrupted.

What is the Success Rate and Treatment Outcomes of CAR T-cell Therapy in India?

CAR T-cell therapy in India has shown highly encouraging results, especially in patients with relapsed or refractory blood cancers. Many hospitals report remission rates of 60% to 80%, depending on the type of cancer and patient condition. For B-cell Acute Lymphoblastic Leukemia (ALL), response rates have been especially promising, even in patients who did not respond to chemotherapy or bone marrow transplants.

What makes these outcomes even more impressive is the rapid access to therapy and strict patient selection protocols, which ensure that only those who are most likely to benefit receive the treatment. With increasing experience, Indian oncologists are continually refining their protocols to enhance both safety and effectiveness.

Clinical results from NexCAR19, India's first domestically developed CAR T-cell product, have also demonstrated a strong safety profile and significant clinical benefits in early trials. Hospitals now follow international treatment protocols, and Indian centers are also part of global clinical research networks, offering patients access to the latest innovations in cancer therapy.

Patients report experiencing quick symptom relief, an improved quality of life, and longer remission periods, especially when treatment is followed by close monitoring and appropriate supportive care.